Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02180867 · OUTCOME

Percentage of Chemoradiotherapy Patients With Positive Pathologic Response at Week 13

Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery · Source last updated 2026-06-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percentage of patients
Interval / dispersion
95% Confidence Interval
Time frame
Week 13 after induction

What was measured

A responder is defined by more than (90% tumor necrosis at week 13). A non-responder has less than 90% necrosis or progressive disease before week 13.

Analysis population: It was pre-specified to combine adult and pediatric participants for analysis as they received an equivalent dose of Pazopanib. There were no patients enrolled onto Dose-Finding Level 0 CR or Dose-Finding Level 2 CR. 19 Regimen A patients and 23 Regimen B patients were excluded.

Groups in this outcome

Dose-Finding Level 1 CR

Dose-Finding Level 1 CR: Adult: Pazopanib 600 mg; Pediatric: Pazopanib 350 mg/m2

Regimen A

Regimen A: Chemoradiation plus pazopanib

Regimen B

Regimen B: Chemoradiation alone

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Dose-Finding Level 1 CR6
Regimen A30
Regimen B25

Reported measurements

Source class 1
Values in Percentage of patients · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Dose-Finding Level 1 CR66.67Not reported28.95100Not reported
Regimen A46.67Not reported28.8164.52Not reported
Regimen B24Not reported7.2640.74Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        28.95
        upper Limit
        100
        value
        66.67
      2. group Id
        OG001
        lower Limit
        28.81
        upper Limit
        64.52
        value
        46.67
      3. group Id
        OG002
        lower Limit
        7.26
        upper Limit
        40.74
        value
        24
denoms
  1. counts
    1. group Id
      OG000
      value
      6
    2. group Id
      OG001
      value
      30
    3. group Id
      OG002
      value
      25
    units
    Participants
description
A responder is defined by more than (90% tumor necrosis at week 13). A non-responder has less than 90% necrosis or progressive disease before week 13.
dispersion Type
95% Confidence Interval
groups
  1. description
    Dose-Finding Level 1 CR: Adult: Pazopanib 600 mg; Pediatric: Pazopanib 350 mg/m2
    id
    OG000
    title
    Dose-Finding Level 1 CR
  2. description
    Regimen A: Chemoradiation plus pazopanib
    id
    OG001
    title
    Regimen A
  3. description
    Regimen B: Chemoradiation alone
    id
    OG002
    title
    Regimen B
param Type
NUMBER
population Description
It was pre-specified to combine adult and pediatric participants for analysis as they received an equivalent dose of Pazopanib. There were no patients enrolled onto Dose-Finding Level 0 CR or Dose-Finding Level 2 CR. 19 Regimen A patients and 23 Regimen B patients were excluded.
reporting Status
POSTED
time Frame
Week 13 after induction
title
Percentage of Chemoradiotherapy Patients With Positive Pathologic Response at Week 13
type
PRIMARY
unit Of Measure
Percentage of patients

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice